Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Pick’s Disease

  • Suzanne MusilEmail author
  • Nancy Johnson
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_508

Synonyms

Behavioral variant frontotemporal dementia; Dementia of frontal lobe type; Frontal lobe dementia

Short Description or Definition

The term “Pick’s disease” has been used to describe a neuropathological entity and/or a clinical syndrome. Pathologists use this term on the basis of the histologic criteria of argyrophilic inclusions (Pick bodies) and ballooned neurons (Pick cells). As a clinical syndrome, Pick’s disease is used to describe progressive alterations in personality and behavior (e.g., frontotemporal dementia [FTD]), and/or language (e.g., progressive aphasia).

Categorization

Developments in molecular pathology have led to the classification of Pick’s disease as a tauopathy, defined neuropathologically by the presence of tau immunoreactive Pick bodies (Lee et al. 2001). Compared to other tauopathies (e.g., progressive supranuclear palsy [PSP] and corticobasal degeneration [CBD]), the distribution of pathology is more likely to be cortical than subcortical, and Pick...

This is a preview of subscription content, log in to check access.

References and Readings

  1. Alzheimer, A. (1911). Uber eigenartige Krankheitsfälle des späteren Alters. Z Gesamte Neurol Psychiat, (4), 356–385.CrossRefGoogle Scholar
  2. Boeve, B. F. (2007). Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Alzheimer Disease and Associated Disorders, 21(4), S31–S38.CrossRefGoogle Scholar
  3. Cummings, J. L. (1997). The neuropsychiatric inventory: Assessing psychopathology in dementia patients. Neurology, 48(5, Suppl. 6), S10–S16.CrossRefGoogle Scholar
  4. Davies, R. R., Hodges, J. R., Kril, J. J., Patterson, K., Halliday, G. M., & Xuereb, J. H. (2005). The pathological basis of semantic dementia. Brain, 128(Pt 9), 1984–1995.CrossRefGoogle Scholar
  5. Feany, M. B., Mattiace, L. A., & Dickson, D. W. (1996). Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. Journal of Neuropathology and Experimental Neurology, 55(1), 53–67.CrossRefGoogle Scholar
  6. Gans, A. (1922). Betrachtungen über art und Ausbreitung des krankhaften Prozesses in einem Fall van Pickscher Atrophie des Stirnhins. Zeitschr fd ges. Neurol u Psychiatr (Berl), 80, 10–28.CrossRefGoogle Scholar
  7. Kertesz, A. (2003). Pick’s complex and FTDP-17. Movement Disorders, 18(Suppl. 6), S57–S62.CrossRefGoogle Scholar
  8. Kertesz, A., Munoz, D., & Hillis, A. (2003). Preferred terminology. Annals of Neurology, 54(Suppl. 5), S3–S6.CrossRefGoogle Scholar
  9. Lee, V. M., Goedert, M., & Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annual Review of Neuroscience, 24, 1121–1159.CrossRefGoogle Scholar
  10. Mackenzie, I. R., & Rademakers, R. (2007). The molecular genetics and neuropathology of frontotemporal lobar degeneration: Recent developments. Neurogenetics, 8(4), 237–248.CrossRefGoogle Scholar
  11. Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Leger, G. C., Rademaker, A., et al. (2008). Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Annals of Neurology, 63(6), 709–719.PubMedCentralCrossRefPubMedGoogle Scholar
  12. Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., et al. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology, 51(6), 1546–1554.CrossRefGoogle Scholar
  13. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., et al. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102(19), 6990–6995.PubMedCentralCrossRefPubMedGoogle Scholar
  14. Pick, A. (1892). Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Med Wochenschr, 17, 165–167.Google Scholar
  15. Rosen, H. J., Hartikainen, K. M., Jagust, W., Kramer, J. H., Reed, B. R., Cummings, J. L., et al. (2002). Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology, 58(11), 1608–1615.CrossRefGoogle Scholar
  16. Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N. C., Rosenmann, H., et al. (2009). NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiology of Disease, 34(2), 381–388.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Rush University Medical CenterChicagoUSA
  2. 2.Cognitive/Behavioral Neurology Center Northwestern Feinburg School of MedicineChicagoUSA